The ADC selectively binds FGFR2b on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage and apoptosis. DNA topoisomerase I is the intracellular payload target, not the antigen used for cell targeting; topo I expression alone does not make cells directly killed by the drug.